Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Weighted Average) (2016 - 2025)

Adma Biologics (ADMA) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $238.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 2.24% year-over-year to $238.3 million, compared with a TTM value of $238.3 million through Dec 2025, up 2.24%, and an annual FY2025 reading of $238.3 million, up 2.24% over the prior year.
  • Shares Outstanding (Weighted Average) was $238.3 million for Q4 2025 at Adma Biologics, roughly flat from $238.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $238.4 million in Q3 2025 and bottomed at $115.7 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $203.0 million, with a median of $223.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 69.35% in 2022, then grew 1.64% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $139.6 million in 2021, then soared by 41.77% to $197.9 million in 2022, then grew by 13.19% to $224.0 million in 2023, then rose by 4.07% to $233.1 million in 2024, then grew by 2.24% to $238.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ADMA at $238.3 million in Q4 2025, $238.4 million in Q3 2025, and $238.3 million in Q2 2025.